Cheng-I Wang

My research interests focus on therapeutic protein and antibody engineering, synthetic biology, and immunotherapy, with the goal of advancing strategies for disease treatment. Through antibody engineering, we aim to design next-generation T-cell engagers and antibody–drug conjugates capable of addressing diverse disease indications. In addition, we have successfully engineered an extensive panel of antibodies targeting immune checkpoints to effectively reactivate the immune system and combat tumors in mouse models. We also developed a unique strategy to activate anti-cancer cytokine pathways through a bispecific receptor agonist antibody design. Building on the antibody engineering technologies established in our laboratory, we have further embarked on the development of Chimeric Antigen Receptor (CAR) T cells with a particular focus on overcoming tumor heterogeneity. Altogether, these studies reflect our ongoing efforts to use antibody and cell engineering to open new possibilities for treating cancer and other diseases.